About PyrAmes & Our Technology
Our Platforms
Presenting Boppli®
Accurate1, non-invasive, continuous, wireless BP monitoring for neonatal and pediatric patients.
Learn More
cNIBP Health Impact
PyrAmes platforms will provide options to continuously monitor blood pressure cNIBP for patients of all ages.
Over 50% of NICU Admissions
could benefit from BP monitoring but would not receive an arterial line because it is invasive and costly.2
50% of Adults have High BP
50% of adults are affected by high blood pressure in the US, increasing their mortality rates.3
7.6 Million Deaths Annually
Raised blood pressure (BP) is responsible for 7.6 million deaths worldwide annually.4
cNIBP & Early Detection
cNIBP has the potential for early detection of conditions within preterm infants and adults.
News & Updates
November 13, 2023
PyrAmes recognized in American Heart Association’s Health Tech Competition
The American Heart Association Center for Health Technology & Innovation selected PyrAmes as the best business pitch by a panel of expert judges at its annual Health Tech Competition during Scientific Sessions 2023. PyrAmes was one of five finalists in AHA’s competition, which aims to drive innovation and foster advancements with the potential to transform the landscape of heart and brain health.
October 10, 2023
TEAMFund Global Health Innovator Award
PyrAmes CEO and Co-founder, Xina Quan, Ph.D., was recognized as the sixth winner of TEAMFund's Annual Global Health Innovator Award and the sixth consecutive Female Founder. TEAMFund, is a 501(c)(3) Public Charity and a For-Profit Impact Fund whose mission is to enhance patient access to medical technology in low-resource settings.
September 29, 2023
PyrAmes Receives FDA Clearance for its Groundbreaking Boppli® Wearable Blood Pressure Monitoring Device
Boppli provides essential clinical information for newborns undergoing critical care
Cupertino, CA, September 29, 2023 — PyrAmes Inc., a digital health company pioneering innovative blood pressure (BP) monitoring solutions, today announced it has received FDA 510(k) clearance for its revolutionary Boppli® platform to continuously and non-invasively monitor the blood pressure of critically-ill infants. Boppli offers safe and accurate BP monitoring as an alternative to invasive arterial lines (IAL) and intermittent cuff-based measurements. Boppli previously received Breakthrough Device Designation from the FDA, recognizing its potential to enable more timely identification of life-threatening conditions. It is the only commercially-available, continuous and non-invasive BP monitoring solution for infants. Boppli improves ease of use and avoids the risks and costs associated with IALs. Boppli also eliminates the cumbersome and time-consuming nature of standard cuff-based measurements, which provide only occasional spot BP values and may be prone to inaccuracies. Boppli accuracy was demonstrated to be within FDA guidelines during a rigorous, pivotal clinical study by comparing Boppli sensor data against simultaneous IAL data for critically ill infants in multiple neonatal intensive care units (NICU) in the U.S. and Canada. (more…)
2023 American Heart Association Health Tech Competition
2023 FDA 510(k) Clearance
2023 NIH RADx Tech Maternal Health Challenge
2020 FDA Breakthrough Device Designation
Founding Member of CDC National Hypertension Control Roundtable